Scientific Advisory Board


Prof. Dr. Cliona Rooney

Center for Cell & Gene Therapy,
Baylor College of Medicine, USA

Cliona Rooney serves in the Department of Pediatrics, Molecular Virology and Microbiology and Immunology and is the Director of the Translational Research Laboratories at the Center for Cell and Gene Therapy at Baylor College of Medicine.

Cliona brings over 20 years of expertise in the field of T cell immunotherapy for virus-associated diseases and cancer. She was instrumental in the development of T-cell therapies virus-specific T-cells in the stem cell transplant setting and has further developed and refined antigen-specific T-cells for the treatment of cancer. Her current interests are in gene modifications and other strategies to render T-cells effective within an immunosuppressive microenvironment.

Dr. Anthony Davies

Dark Horse Consulting Inc., USA

After training as a biochemist, chemical engineer and molecular biologist, Anthony Davies has worked in the cell and gene therapy field for some 20 years. Over this period he has held positions of increasing responsibility at companies including Onyx Pharmaceuticals, Geron Corporation and Capricor.

He is now president of Dark Horse Consulting (DHC), a boutique practice focussed on CMC and product development issues in monoclonal antibody, cell and gene therapies. DHC is based in California and has a European office in London – its clients range from academic institutions, through small and mid-sized companies to global pharmaceutical companies.

Dr. Mitchell H. Finer

MPM Capital, USA

Mitch Finer has over 30 years of experience in the areas of regenerative medicine, cancer immunotherapy and cell and gene therapy, where he helped to advance products from conception through phase III clinical programs. 

Mitch founded Oncorus and currently serves as CEO and CSO. In 2015 he joined MPM Capital as Managing Director and is a member of the board of directors of MPM portfolio company Semma Therapeutics. Prior to MPM, Mitch served as CSO of bluebird bio, where he was responsible for strategic elaboration of bluebird’s gene-modified adult hematopoietic stem cell therapy business and led the strategic development and partnering of CAR-T and genome engineering programs.